ArticleJournal of gastrointestinal cancer2025
Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer.
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic utility of the Charlson comorbidity index in pancreatic cancer: a systematic review and meta‑analysis.World journal of surgical oncology · 2026Pooled it
- Social Progress Index as a Determinant of Healthcare Access and Treatment in Pancreatic Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeFive-year survival for pancreatic adenocarcinoma (PDAC) is < 10% but can vary by a patient's race, socioeconomic status (SES), and the factors related to the neighborhood where a patient lives (nSES) . Prolonged time from diagnosis to first treatment (T2T) is another important disparity indicator. Here, we examined the effect of race, nSES, and patient-level clinical factors on T2T and survival in metastatic PDAC (mPDAC) patients.
methodsPatients with mPDAC treated at an academic cancer center between 2010 and 2018 (n = 334) were evaluated for nSES measures related to racial concentration, neighborhood deprivation, stability, immigration status, and transportation access from the US Census. We assessed and reported the effects of nSES and patient-level variables (age, race, gender, Charlson Comorbidity Index (CCI), etc.) on T2T and survival using univariate and multivariate Cox proportional hazards regression, hazard ratios (HR), confidence intervals (CI).
results82.9% of the patients were White; 17.1% were Black. Median T2T was 26 days with no significant difference in T2T and survival by race. In multivariable models, no nSES variables were significantly associated with T2T. T2T did not significantly impact survival; however, receipt of chemotherapy (HR = 0.14 [95% CI = 0.06, 0.30]) was associated with better survival outcomes.
conclusionAmong patients with mPDAC, T2T was not associated with race/ethnic disparities or survival in a mostly White, high SES population treated at a comprehensive cancer center. Future investigations into pancreatic cancer disparities may be warranted in other hospital settings and in larger, more diverse study samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.